PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced plans to showcase updated clinical data on its investigational CD19-CAR T cell therapy, resecabtagene autoleucel (rese-cel), during two prominent scientific conferences this February. The data, drawn from the first 10 patients treated in the RESET clinical development program, highlight the potential of rese-cel to revolutionize treatment for autoimmune diseases by reprogramming immune responses.
The first presentation will take place during the 2025 American Association for the Advancement of Science Annual Meeting in Boston, MA, on February 15, 2025. Aimee Payne, M.D., Ph.D., co-founder of Cabaletta Bio and leading dermatologist at Columbia University, will present key findings under the topic “Unleashing Immune Cells on Autoimmune Disease.” Shortly after, Samik Basu, M.D., Chief Scientific Officer at Cabaletta Bio, will present at the 5th International Conference on Lymphocyte Engineering in Munich, Germany, on February 22, 2025, under the session “Targeting Non-malignant Diseases.”
Rese-cel is a fully human, 4-1BB-containing anti-CD19 CAR T cell therapy being investigated for its ability to transiently clear CD19-positive cells in autoimmune patients. By doing so, the therapy aims to reset the immune system and deliver lasting clinical benefits without the need for chronic treatment. Currently, this innovative approach is being evaluated in the RESET (REstoring SElf-Tolerance) clinical program across multiple autoimmune conditions, such as systemic sclerosis, systemic lupus erythematosus (SLE), and myositis.
The therapy’s mechanism and clinical results underscore its potential to provide game-changing outcomes for patients by addressing the root causes of autoimmune diseases rather than simply managing symptoms. Cabaletta Bio’s progress to date demonstrates not only advancing scientific pathways but also tangible hope for individuals affected by debilitating autoimmune disorders.
Looking ahead, Cabaletta Bio stated it remains committed to releasing top-tier clinical insights as its RESET trials advance, offering a new vision for the treatment of autoimmune diseases. The forthcoming data shared at leading international meetings reinforce rese-cel’s promise as a groundbreaking therapeutic option in the fight against complex immune system disorders.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.